Get the Stockscreener App
0.3474
5.37%
0.0177
After Hours:
.34
-0.0074
-2.13%
Gossamer Bio Inc stock is traded at $0.3474, with a volume of 6.91M.
It is up +5.37% in the last 24 hours and down -30.62% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$0.3297
Open:
$0.3452
24h Volume:
6.91M
Relative Volume:
0.46
Market Cap:
$81.53M
Revenue:
$48.47M
Net Income/Loss:
$-170.37M
P/E Ratio:
-0.4633
EPS:
-0.7499
Net Cash Flow:
$-171.35M
1W Performance:
-4.82%
1M Performance:
-30.62%
6M Performance:
-85.64%
1Y Performance:
-55.91%
1-Day Range:
$0.3222
$0.3494
1-Week Range:
$0.32
$0.3814
52-Week Range:
$0.32
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3474 | 77.38M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
GOSS Investor Alert: Gossamer Bio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects - marketscreener.com
Cantor Fitzgerald downgrades Gossamer Bio (GOSS) to neutral - MSN
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Yahoo Finance
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
Holzer & Holzer, LLC Reminds Investors of June 1, 2026 Lead - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) - The National Law Review
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Stop Loss: Is Gossamer Bio Inc part of any ETFMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - Sahm
Gossamer Bio Lawsuit: Investors Allege Misleading Statements Ahead of Failed PAH Trial - TipRanks
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - lincolnjournal.com
User - The Chronicle-Journal
Investors Seek Lead in Gossamer Bio Securities Fraud Lawsuit - nationaltoday.com
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – GOSS - ChartMill
GOSS Investors Invited to Lead Securities Fraud Lawsuit Against Gossamer Bio - nationaltoday.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming DeadlinesGOSS - ChartMill
GOSS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Gossamer Bio, Inc. - ChartMill
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - lincolnjournal.com
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - stocktitan.net
Gossamer Bio, Inc. (4GB.MU) stock price, news, quote and history - Yahoo Finance Australia
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit - The AI Journal
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – ... - Caledonian Record
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - WBOC TV
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - PR Newswire
Trading Action: Is Gossamer Bio Inc stock a smart retirement pick2026 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
683 Capital Management, LLC Reduces Stake in Gossamer Bio Inc - GuruFocus
Gossamer Bio (GOSS) price target decreased by 53.60% to 4.44 - MSN
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - insidermonkey.com
Gossamer Bio Receives 'Hold' Rating from Analysts - National Today
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Vanguard reports zero beneficial holdings in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Cantor Fitzgerald downgrades Gossamer Bio (GOSS) - MSN
GOSS (Gossamer Bio) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - PR Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Legal Scrutiny Intensifies for Gossamer Bio Following Clinical Trial Setback () - aktiencheck.de
Options Flow: Is Gossamer Bio Inc a stock for growth or value investorsPortfolio Performance Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio (GOSS) continues downtrend despite impressive revenue - MSN
Setup Watch: Should I set a stop loss on Gossamer Bio IncTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):